Daishi Tian
Clinical trials sponsored by Daishi Tian, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could CAR-T cells tame multiple sclerosis? early trial launches Results expected Jan 2027 (estimated)
- Experimental CAR-T therapy takes aim at Tough-to-Treat myasthenia gravis Results expected Feb 2027 (estimated)
- Experimental STAR-T cell therapy aims to tame multiple sclerosis Results expected Apr 2027 (estimated)
- Engineered immune cells take aim at debilitating muscle weakness Results expected Jul 2027 (estimated)
- CAR-T cells take on stubborn muscle disease in first human test Results expected Sep 2027 (estimated)
-
Could CAR-T cells tame multiple sclerosis? early trial launches
Disease control Recruiting nowThis early study tests a single dose of GC012F CAR-T cell injection in 9 people with multiple sclerosis. The main goal is to check safety and tolerability, not yet to see if it works. Researchers will monitor side effects for up to 15 years and measure how the cells behave in blo…
Early phase 1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
CAR-T cells take on stubborn muscle disease in first human test
Disease control Recruiting nowThis early-phase trial tests a new treatment called GC012F, which uses a patient's own immune cells (CAR-T cells) to target and attack the cause of idiopathic inflammatory myopathy, a group of rare muscle diseases. The study will enroll 12 adults whose disease has not responded t…
Early phase 1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Experimental CAR-T therapy takes aim at Tough-to-Treat myasthenia gravis
Disease control Recruiting nowThis early study tests a new treatment called GC012F, made from a patient's own immune cells (CAR-T cells), for people with refractory generalized myasthenia gravis that hasn't responded to standard therapies. Six participants will receive a single infusion of these modified cell…
Early phase 1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated Jun 26, 2026 15:19 UTC